Science Pool

Evotec's partner Exscientia reports topline data from EXS-21546 phase 1A study

Evotec’s partner Exscientia plc today announced data from its Phase 1 healthy volunteer study of EXS-21546, its highly selective A2a receptor antagonist co-invented and developed through a collaboration between Exscientia and Evotec SE.

Read More

Twitter
LinkedIn
Email